Use of heated tobacco products, moderate alcohol drinking, and anti-SARS-CoV-2 IgG antibody titers after BNT162b2 vaccination among Japanese healthcare workers일본 의료 종사자의 BNT162b2 예방 접종 후 가열 담배 제품, 적당한 음주 및 항 SARS-CoV-2 IgG 항체 역가 사용Article Published on 2022-08-012022-09-12 Journal: Preventive medicine [Category] MERS, 진단, [키워드] addition alcohol alcohol consumption Analysis anti-SARS-CoV-2 anti-SARS-CoV-2 IgG antibody Antibody titer association BNT162b2 BNT162b2 vaccine collected coronavirus disease covariates COVID-19 COVID-19 vaccine enzyme geometric mean titer GMT group healthcare worker Heated tobacco products IgG antibody titer immunoassay immunogenicity Immunological response Japan Japanese Linear regression model moderate National participant predictor questionnaire receiving reduction Research Result second vaccination serum significantly lower smoker smoking spike IgG the median vaccination Vaccine vaccine dose were assessed were measured were used [DOI] 10.1016/j.ypmed.2022.107123 PMC 바로가기 [Article Type] Article
Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients폐 이식 환자에서 2차 및 3차 SARS-CoV-2 백신에 따른 혈청학적 소견Article Published on 2022-08-012022-09-12 Journal: Immunity, Inflammation and Disease [Category] SARS, 진단, [키워드] acute respiratory syndrome age antibody Antibody titer average BBIBP-CorV booster Booster vaccine ChAdOx1 Clinical data coronavirus coronavirus disease COVID COVID-19 died difference dose doses effective enrolled evaluated had no highest ICU IgG immunization Immunocompromised patients Immunoglobulin Immunological response induce Infection injection intensive care lung transplant median men Messenger RNA mRNA mRNA vaccine mRNA-1273 mRNA-based non-mRNA vaccine pandemic Patient patients positive recipient SARS-CoV-2 SARS-CoV-2 vaccine second dose serology Serum level significantly higher STABLE Support therapy third vaccination Transplant U/mL Vaccine was measured were given [DOI] 10.1002/iid3.646 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials동종 또는 이종 체계에서 항 SARS CoV-2 백신 SOBERANA 02의 안전성 및 면역원성: 공개 라벨 임상 1상 및 2a상 임상 시험Clinical Trial Published on 2022-07-292022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] adaptive adverse event Anti-RBD IgG Antigen clinical trial clinical trials conjugate Conjugate vaccine COVID-19 COVID-19 vaccine D614G delta variant dose doses elicited ELISA evaluate evaluated frequencies Frequency hACE2 Heterologous heterologous immunization Heterologous immunization scheme homologous homologous or heterologous IgG IgG ELISA IIa immune response immune responses immunogenic immunogenicity Immunological response Interaction local pain molecular neutralization neutralized Neutralizing antibodies neutralizing antibody Open-label outcome Panel performed phase Phase I phase IIa Primary outcome progressed protocol protocols RBD receive receiving reduction reported Safe Safety SARS-CoV-2 secondary outcome selected Specific T-cell response subjects Subunit vaccine T-cell T-cell Response T-cells Tetanus tetanus toxoid trials Vaccine variant Volunteer volunteers [DOI] 10.1016/j.vaccine.2022.05.082 PMC 바로가기 [Article Type] Clinical Trial
Antibody response to the messenger RNA-1273 vaccine (Moderna) in liver transplant recipients간 이식 환자에서 메신저 RNA-1273 백신(모더나)에 대한 항체 반응Article Published on 2022-07-012022-09-12 Journal: Hepatology communications [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered anti-S anti-S IgG antibody cause clinical coronavirus coronavirus disease COVID-19 COVID-19 infection develop dose evaluated examined Factor first vaccination Follow-up General population Hepatitis IgG Immunoglobulin Immunological response immunosuppressive include interquartile range laboratory data liver Liver transplantation Logistic regression LTR LTRs median median age men Messenger RNA Moderna MOST Most patient mRNA mRNA-1273 vaccine mRNA-based vaccine Odds ratio Patient positive predict receiving recipient recipients regimen response RNA-1273 SARS-CoV-2 Serologic response shown tested the spike protein the vaccine university Vaccine vaccine dose [DOI] 10.1002/hep4.1937 PMC 바로가기 [Article Type] Article
BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All AgesBNT162b2 부스터 백신 접종은 모든 연령대의 회복기에서 SARS-CoV-2 변이체 B.1.1.529 및 B.1.617.2에 대한 교차 반응성 면역을 유발합니다Observational Study Published on 2022-06-202022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 임상, 치료기술, [키워드] Against analyzed anti-spike antibody antigenic approach B.1.1.529 B.1.617.2 BNT162b2 booster vaccination cellular cohort study component convalescent individual convalescent individuals COVID-19 COVID-19-convalescent individual COVID-19-convalescent individuals cross-reactive immune Delta detectable exhibited full recovery IFN-γ immune response Immunological response inactivated include individual individuals memory memory immune response mRNA mRNA vaccine mRNA vaccines neutralization neutralization capacity no significant differences Older omicron parameter prospective observational cohort SARS-CoV-2 second vaccination secretion serological serological response significant difference South Africa Support vaccination Vaccine variant variants of concern virus VoC whole virus vaccine wild type [DOI] 10.3389/fimmu.2022.920210 PMC 바로가기 [Article Type] Observational Study
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRandomized Controlled Trial Published on 2022-06-092022-10-05 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 유전자 메커니즘, 임상, 진단, [키워드] 95% CI addition Adjusted analysis anti-SARS-CoV-2 anti-Spike IgG Antibody Response assigned AstraZeneca baseline benefit BNT162b2 booster Cellular immune response ChAdOx1 ChAdOx1 nCoV-19 Cohort COVID-19 vaccine dose Effect eight EudraCT Evidence Exploratory analyses Exploratory analysis finding funding Future geometric mean concentration geometric mean ratio group groups Heterologous heterologous vaccine homologous humoral humoral immunogenicity immune persistence immune response immunogenic immunogenicity analysis Immunological response intention-to-treat interval intervals ISRCTN ITT ITT analysis less Older participant persistence Pfizer/BioNTech platform priming randomised Randomly reactogenic reactogenicity reduced Registered SARS-COV-2 infection second dose significant difference significantly higher spike IgG study groups Support T-cell Response the vaccine titre Trial Vaccine Virus neutralisation [DOI] 10.1016/S2213-2600(22)00163-1 [Article Type] Randomized Controlled Trial
How to Restore Oxidative Balance That Was Disrupted by SARS-CoV-2 InfectionSARS-CoV-2 감염으로 교란된 산화 균형을 회복하는 방법Review Published on 2022-06-072022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition angiotensin antioxidant antioxidants Antioxidative balance caused Clinical studies clinical study complex coronavirus coronavirus 2019 disease Course COVID-19 COVID-19 pathogenesis cytokine Cytokine storm demonstrated detrimental disease Disrupted drug dysregulated Effect expression glutathione GSH homeostasis Immunological response Impact induce Inflammasome inflammasomes inhibit mechanism NLRP3 Nrf2 nuclear outcome oxidative oxidative stress oxygen Prevent Protective Protein protein 3 reactive oxygen species reactive oxygen specy Renin renin angiotensin system ROS SARS-CoV-2 severe acute respiratory syndrome Coronavirus shown stimulate the disease variant variety virus [DOI] 10.3390/ijms23126377 PMC 바로가기 [Article Type] Review
Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccineBNT162b2 백신의 3차 접종 전후에 항-SARS-CoV-2 S-RBD IgG 항체의 종단적 분석Article Published on 2022-05-232022-09-12 Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] age Analysis anti-SARS-CoV-2 Anti-spike antibody antibody level Antibody Response baseline BNT162b2 vaccine COVID-19 vaccine decrease domain dose doses Efficacy evaluate female healthy individual IgG IgG antibody IgG level Immunity Immunological response immunosurveillance independent indirect chemiluminescence immunoassay individual induce Infection longitudinal males naïve Protein reactivity recipients respiratory response S-RBD SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV2 infection Sex SNIBE Steady state Support the vaccine Trigger Vaccine vaccine doses [DOI] 10.1038/s41598-022-12750-z PMC 바로가기 [Article Type] Article
Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine혈청전환 패널은 mRNA-1273 백신 투여 후 항-SARS-CoV-2 항체 개발을 보여줍니다Article Published on 2022-05-112022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] administration analyzed anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG antibody Antibody Response anticipated collected COVID-19 disease facilitate first vaccination healthcare worker IgG Immunity immunoglobulins Immunological response individual injection Moderna mRNA-1273 vaccine older subjects overcome pandemic Panel positive positive response pre-vaccination SARS-CoV-2 second dose Seroconversion Seroconversion panel Serological assay significantly subject tested the vaccine vaccination Vaccine viral disease [DOI] 10.1016/j.vaccine.2022.04.006 PMC 바로가기 [Article Type] Article
Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: An open-label pilot studyCOVID-19에 대한 새로운 보조 요법으로서 장내 미생물총 유래 신바이오틱 포뮬라(SIM01): 오픈 라벨 파일럿 연구Article Published on 2022-05-012022-09-12 Journal: Journal of gastroenterology and hepatology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Admission Analysis antibody formation Antibody Response bacterial specy bifidobacteria changes in commensal bacteria Control control group controls COVID-19 COVID-19 patient database Day develop discharge Effect fecal greater Gut gut microbiota healthy Hong Kong hospital hospitalised COVID-19 patients hospitalized COVID-19 patients IgG antibody IL-1ra immune dysfunction immune markers Immunity Immunological response IMPROVE independent Infectious disease Intervention M-CSF Macrophage MCP-1 metagenomic microbiota monocyte chemoattractant protein-1 nasopharyngeal nasopharyngeal viral load Necrosis Open-label outcome pathogen Patient pilot study plasma positive pro-inflammatory Probiotics proinflammatory protocol receive receiving reduced restored SARS-CoV-2 SARS-CoV-2 IgG antibody SARS-CoV-2 viral load severity of COVID-19 significant negative correlation significantly standard treatment Strains suggested therapy TNF-α were given [DOI] 10.1111/jgh.15796 PMC 바로가기 [Article Type] Article